Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
*Pseudotsuga menziesii* pollen is a biological extract derived from the pollen of the Douglas fir tree, a conifer native to western North America. It is primarily utilized as a diagnostic allergen in skin prick testing or in vitro assays to identify individuals with hypersensitivity to Douglas fir pollen. The extract contains various proteins that trigger an IgE-mediated allergic response in sensitized individuals, allowing for the confirmation of allergic rhinitis or asthma triggered by this specific tree species. The product is recognized in pharmacological databases such as DrugBank (DB10986) and is produced by specialized allergen manufacturers for clinical use in allergy testing.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on pseudotsuga menziesii pollen.